UK – Gilead’s CAR-T cell therapy recommended by NICE for lymphoma
Gilead Science and Kite, a Gilead company, have announced that the National Institute for Health and Care Excellence (NICE) has recommended Yescarta (axicabtagene ciloleucel) to treat certain forms of lymphoma.
Specifically, the therapy is now recommended for adult patients with diffuse large B-cell lymphoma (DLBCL) or primary mediastinal large B-cell lymphoma (PMBCL) who have already been treated with two or more systemic therapies.
The decision from NICE makes Yescarta the first chimeric antigen receptor (CAR) T-cell therapy to be recommended for routine use on the NHS.
More information on the RIS.WORLD Website.
OpenEdition vous propose de citer ce billet de la manière suivante :
vroby (19 avril 2023). UK – Gilead’s CAR-T cell therapy recommended by NICE for lymphoma. ELSIBI. Consulté le 19 février 2026 à l’adresse https://doi.org/10.58079/o68x





